Capello Jeffrey D
SEC-identified person · CIK 1224108 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Agios Pharmaceuticals, INC. AGIO | Director | filed 2023–2026 |
| Neogen Corp neogen9$ | Director | filed 2022–2025 |
| Biogen INC. BIIB | EVP & Chief Financial Officer | filed 2017–2020 |
| Tempest Therapeutics, Inc. TPST | Director | filed 2012–2018 |
| Salarius Pharmaceuticals, Inc. SLRX | Director | filed 2015–2017 |
| Boston Scientific Corp bsx | SVP, Chief Accounting Officer | filed 2008–2013 |
| Revvity, INC. RVTY | SVP & CFO | filed 2006–2008 |
| Sirtris Pharmaceuticals, Inc. SIRT | Director | filed 2008–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.